Kate Haviland.

Kate Haviland runs Blueprint Medicines, a precision therapy company developing targeted medicines for cancers and rare genetic diseases driven by specific genomic alterations.

Under her leadership, Blueprint has commercialized multiple approved products, including Ayvakit - a treatment for systemic mastocytosis that has become one of the most commercially successful rare disease products in recent biotechnology history. Haviland joined Blueprint as Chief Operating Officer before rising to CEO, and her operational discipline has been credited with allowing the company to commercialize multiple precision therapies while continuing to advance a deep pipeline of additional development-stage assets. She was named the 2025 EY Entrepreneur of the Year National Life Sciences Award winner. Her tenure at Blueprint represents the maturation of precision medicine as a category: moving from early-stage research promise to approved products generating significant commercial revenue and meaningfully improving outcomes for patients with rare and aggressive diseases. Most precision medicine companies never make it through that transition. Blueprint did, and her operational execution is the reason.